Eppendorf grows faster than the market
During the first half of 2017, the Eppendorf Group achieved group sales of €327.9 million (prior-year period: €305.5 million). At 7.3% (6.6% when adjusted for currency effects), growth in sales lay above average market growth in the life science industry. Income from operations (EBIT) climbed 9.1% to €63.2 million (prior-year period: €58.0 million), amounting to an EBIT margin of 19.3% (prior year: 19.0%). All of the Eppendorf Group’s market regions and product groups contributed to this positive overall development.
Thomas Bachmann, President & CEO of Eppendorf AG, was very pleased at this positive development: “The mid-year result shows that we outperformed the market during the first half of this year. We are currently working on digitalizing our product portfolio and the connectivity of our devices with our new generation of networked products, which we launched on the market during the first six months of the year. We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
ZEISS: High-Tech Drives Growth - Medical technology and industrial metrology business still on track for growth

Innophore GmbH - Graz, Austria
OctoPlus appoints Jan Hendrik Egberts as CEO

Microscaffolds – a New Strategy in Tissue Engineering - Living cells meet high-resolution 3D printing process

Merck Appoints New Executive Board Members - Bernd Reckmann to retire

Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.
AlgoNomics appoints Philippe Stas as CEO - Founder Dr. Ignace Lasters remains CSO and director of the company
